Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for
 the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type
 infections and clinical negative conversion.

 285 patients with positive high risk HPV infection were randomized into interferon gel group
 and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control
 group). The patients in treatment group received 1g recombinant human α-2b interferon gel
 every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in
 control group.
Inclusion Criteria:

 1. Age 30 to 65 years of age the sex life of female patients;

 2. , liquid-based cytology (TCT) check no intraepithelial lesions and malignant cells;

 3. , HPV DNA typing test for high-risk HPV positive (including a single high-risk type
 positive, and more high-risk type of positive and high-and low-risk hybrid positive).

 15 kinds of high-risk types, including HPV16, 18,31,33,35,39,45,51,52,53,56,58,59,66,68

 Exclusion Criteria:

 -  (1) cervical intraepithelial neoplasia (CIN); (2), combined with a severe fungal,
 trichomonas vaginitis; (3), severe primary diseases associated with cardiovascular,
 liver, kidney and hematopoietic system; (4), allergies or allergy to the drug known
 ingredients. (5), within 30 days to accept other clinical trials of drugs or are
 participating in clinical trials; (6), pregnant and lactating women and to be pregnant
 women; (7), the researchers do not consider it appropriate clinical trials.